Literature DB >> 6976312

Suppression of human T-cell mitogenesis and E-rosette formation by the monoclonal antibody OKT11A.

J Van Wauwe, J Goossens, W Decock, P Kung, G Goldstein.   

Abstract

OKT11A, a monoclonal anti-human T-cell antibody was studied for its in vitro effects on lymphocyte functions. At a concentration as low as 10 ng/ml, OKT11A significantly suppressed T-cell proliferation induced by OKT3, purified protein derivative (PPD), tetanus toxoid and allogeneic non-T cells. Total inhibition of proliferation was noticed at concentrations of 1-10 microgram OKT11A/ml. The antibody was only fully effective when added to stimulated cell cultures within the first 2 hr of the culturing period. OKT11A also blocked total and active sheep erythrocyte (E)-rosette formation by T lymphocytes: this activity closely paralleled the suppression of proliferative response. Quantitative studies on the binding of 125I-labelled IKT11A indicated that an average of 2 x 10(4) antibody molecules were bound per T cell. Taken together, these findings show that OKT11A recognizes a sparsely represented T-cell surface determinant that is associated with the inhibition of mitogenic responsiveness and E-rosette formation. Furthermore, our data imply that the E-rosette receptor of T cells is involved in the regulation of immune functions.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6976312      PMCID: PMC1554993     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  19 in total

1.  Study of human T and B lymphocytes with heterologous antisera. I Preparation, specificity and properties of antisera.

Authors:  J Brochier; Y A Abou-Hamed; J P Gueho; J P Revillard
Journal:  Immunology       Date:  1976-11       Impact factor: 7.397

2.  Analysis of cell surfaces by xenogeneic myeloma-hybrid antibodies: differentiation antigens of rat lymphocytes.

Authors:  A F Williams; G Galfrè; C Milstein
Journal:  Cell       Date:  1977-11       Impact factor: 41.582

Review 3.  Characterization of human T-cell subpopulations as defined by specific receptors for immunoglobulins.

Authors:  L Moretta; M Ferrarini; M D Cooper
Journal:  Contemp Top Immunobiol       Date:  1978

4.  Chemical nature of the receptor site for various phytomitogens.

Authors:  S Toyoshima; M Fukuda; T Osawa
Journal:  Biochemistry       Date:  1972-10-10       Impact factor: 3.162

5.  Binding of affinity cross-linked oligomers of IgG to cells bearing Fc receptors.

Authors:  D M Segal; E Hurwitz
Journal:  J Immunol       Date:  1977-04       Impact factor: 5.422

6.  Monoclonal anti-human T-lymphocyte antibodies: enumeration and characterization of T-cell subsets.

Authors:  J Van Wauwe; J Goossens
Journal:  Immunology       Date:  1981-01       Impact factor: 7.397

7.  Diversity of cell surface polypeptides that are recognized by heteroantisera to human T cells.

Authors:  P Niaudet; M Greaves
Journal:  J Immunol       Date:  1980-03       Impact factor: 5.422

8.  In vitro rosette inhibition by antihuman antilymphocyte serum. Correlation with skin graft prolongation in subhuman primates.

Authors:  J F Bach; J Dormont; M Dardenne; H Balner
Journal:  Transplantation       Date:  1969-09       Impact factor: 4.939

9.  Human T cell differentiation antigens and correlation of their expression with various markers of T cell maturation.

Authors:  L Boumsell; A Bernard; H Coppin; Y Richard; C Penit; P Rouget; J Lemerle; J Dausset
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

10.  Detection, isolation, and functional characterization of two human T-cell subclasses bearing unique differentiation antigens.

Authors:  R L Evans; J M Breard; H Lazarus; S F Schlossman; L Chess
Journal:  J Exp Med       Date:  1977-01-01       Impact factor: 14.307

View more
  30 in total

1.  Peripheral T-lymphocyte activation by human T-cell leukemia virus type I interferes with the CD2 but not with the CD3/TCR pathway.

Authors:  M D Dodon; A Bernard; L Gazzolo
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

2.  Expression of the T-cell surface molecule CD2 and an epitope-loss CD2 mutant to define the role of lymphocyte function-associated antigen 3 (LFA-3) in T-cell activation.

Authors:  B E Bierer; A Peterson; J Barbosa; B Seed; S J Burakoff
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

3.  A feline CD2 homologue interacts with human red blood cells.

Authors:  Masayuki Shimojima; Yorihiro Nishimura; Takayuki Miyazawa; Kentaro Kato; Kazuya Nakamura; Yoshihiro Izumiya; Hiroomi Akashi; Yukinobu Tohya
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

4.  Implantation site in normal pregnancy. A study with monoclonal antibodies.

Authors:  S E Kabawat; M Mostoufi-Zadeh; S G Driscoll; A K Bhan
Journal:  Am J Pathol       Date:  1985-01       Impact factor: 4.307

5.  Modulatory anti-T antibody on mature human lymphocytes.

Authors:  A Nouri; H Festenstein
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

6.  Monoclonal antibodies which react with bovine T-lymphocyte antigens and induce blastogenesis: tissue distribution and functional characteristics of the target antigens.

Authors:  C L Baldwin; N D Machugh; J A Ellis; J Naessens; J Newson; W I Morrison
Journal:  Immunology       Date:  1988-03       Impact factor: 7.397

Review 7.  Atopic allergy in relation to cell-mediated immunity.

Authors:  B Björkstén
Journal:  Clin Rev Allergy       Date:  1984-05

8.  Lymphocyte compartments in human spleen. An immunohistologic study in normal spleens and uninvolved spleens in Hodgkin's disease.

Authors:  W Timens; S Poppema
Journal:  Am J Pathol       Date:  1985-09       Impact factor: 4.307

9.  Intracellular mediators regulate CD2 lateral diffusion and cytoplasmic Ca2+ mobilization upon CD2-mediated T cell activation.

Authors:  S J Liu; W C Hahn; B E Bierer; D E Golan
Journal:  Biophys J       Date:  1995-02       Impact factor: 4.033

Review 10.  T cell targeting in cancer therapy.

Authors:  R L Bolhuis; E Sturm; E Braakman
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.